No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
VSTM250117P8000
- 2.50
- +0.50+25.00%
15min DelayClose Jan 10 16:00 ET
2.50High2.50Low
2.50Open2.00Pre Close1 Volume1 Open Interest8.00Strike Price250.00Turnover474.13%IV4.01%PremiumJan 17, 2025Expiry Date2.27Intrinsic Value100Multiplier7DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type-0.5732Delta0.1050Gamma1.85Leverage Ratio-0.1088Theta-0.0011Rho-1.06Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
Express News | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Is Maintained at Outperform by RBC Capital
Verastem Analyst Ratings
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $16
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9